The role of NK cells during acute HCV infection and antiviral therapy
The role of NK cells during acute HCV infection and antiviral therapy
批准号:
7919782
负责人:
Galit Alter
金额:
$17.12万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-01 至 2015-07-31
关键词:
AcuteAllelesAntigensAntiviral AgentsAntiviral TherapyCellsChronic Hepatitis CClonal ExpansionComplement component C1sContainmentCytolysisEffector CellEpidemiologyFamilyGenotypeHLA-C AntigensHepatitis CHepatitis C virusImmune responseImmune systemIndividualInfectionInterferonsLigandsLiverMediatingMetabolic Clearance RateNatural Killer CellsPatientsPhenotypePlayPopulationPropertyReceptor GeneResolutionRoleViralVirusVirus Diseaseskiller immunoglobulin-like receptornovelreceptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Increasing evidence supports a central role for the innate immune system in the host's response against viral
infections. In particular, natural killer (NK) cells represent a critical eariy cytolytic effector cell subset that are
able to spontaneously lyse virally infected cells without the need for prior anfigen sensitizafion. In the context
of HCV infecfion, a small number of studies have focused on this cell subset as these cells have been
implicated in the eariy control of a number of viral infecfions, these cells are abundant within the liver, and
that in addition to the direct antiviral effects of interferon(IFN)-a (used to treat the infection), IFN-a directly
acfivates the antiviral capacity of NK cells. Furthermore, compelling epidemiologic evidence has identified a
strong association between homozygosity of NK killer immunoglobulin-like receptor gene {KIR2DL3) and its
ligand HLA-C alleles in the Cl family, suggesting that NK cells may truly play a central role in this antiviral
protection. However the direct role of NK cells in HCV clearance still remains to be determined.
Accumulating evidence suggests that chronic HCV infection is associated with the accumulafion of a
phenotyplcally and potentially functionally altered NK cells. However, HCV resolution occurs within the first
weeks to months of HCV infection in 15-30% of infected individuals. This eariy control occurs at a fime when
the adaptive immune response is just being induced. Thus several groups have speculated that innate,
including NK cells, rather than adaptive immune responses may play a major role in eariy containment. Thus
in this proposal we aim to define the role of NK cells in acute HCV infecfion and to determine the NK cell
immunolpgical signatures associated with the ability to clear HCV infecfion. Thus we propose to first carefully
phenotyplcally, transcriptionally, and functionally characterize NK cells in acute HCV infection among
individuals that resolve compared to those that become chronically infected; to then dissect the role of the
protecfive KIR2DL3/HLA-C1 combined genotype on NK cell clonal expansions and antiviral funcfion; and
finally to investigate how IFN-a and other IFNs may contribute to the specific expansion and funcfional
activafion of protective NK cell populations with unique antiviral properties. Elucidafing the role of NK cells in
the resolution of HCV infection may provide potentially novel opportunifies to enhance the activity of
particular NK cell populafions to gain greater control over the virus and enhance HCV clearance rates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SARS-CoV-2 Variant Testing
-
批准号:10446500
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Systems Serology Core
-
批准号:10616544
-
项目类别:
-
资助金额:$29.45万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Systems Serology Core
-
批准号:10203487
-
项目类别:
-
资助金额:$39.61万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Systems Serology Core
-
批准号:10449292
-
项目类别:
-
资助金额:$40.74万
-
财政年份:2021
-
负责人:Galit Alter
-
依托单位:
Defining humoral correlates of immunity against COVID-19
-
批准号:10265799
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2020
-
负责人:Galit Alter
-
依托单位:
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
-
批准号:10221341
-
项目类别:
-
资助金额:$147.8万
-
财政年份:2020
-
负责人:Galit Alter
-
依托单位:
Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children
-
批准号:10159844
-
项目类别:
-
资助金额:$96.06万
-
财政年份:2020
-
负责人:Galit Alter
-
依托单位:
Antibody Optimization Core
-
批准号:10158451
-
项目类别:
-
资助金额:$68.97万
-
财政年份:2019
-
负责人:Galit Alter
-
依托单位:
Antibody Optimization Core
-
批准号:10402341
-
项目类别:
-
资助金额:$69.29万
-
财政年份:2019
-
负责人:Galit Alter
-
依托单位:
Antibody Optimization Core
-
批准号:10617741
-
项目类别:
-
资助金额:$62.43万
-
财政年份:2019
-
负责人:Galit Alter
-
依托单位:
Core B
-
批准号:10339364
-
项目类别:
-
资助金额:$99.39万
-
财政年份:2018
-
负责人:Galit Alter
-
依托单位:
Killing the Reservoir with Antibodies
-
批准号:9197410
-
项目类别:
-
资助金额:$48.61万
-
财政年份:2015
-
负责人:Galit Alter
-
依托单位:
Killing the Reservoir with Antibodies
-
批准号:8656251
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2013
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8408897
-
项目类别:
-
资助金额:$60.99万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8874097
-
项目类别:
-
资助金额:$87.64万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8691723
-
项目类别:
-
资助金额:$84.27万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
Tuning Fc-effector functions of HIV-specific antibodies
-
批准号:8496714
-
项目类别:
-
资助金额:$67.25万
-
财政年份:2012
-
负责人:Galit Alter
-
依托单位:
The Innate Immune Signals on B Cells that Induce ADCC Antibodies
-
批准号:8332408
-
项目类别:
-
资助金额:$43.79万
-
财政年份:2011
-
负责人:Galit Alter
-
依托单位:
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp
-
批准号:8072923
-
项目类别:
-
资助金额:$43.39万
-
财政年份:2010
-
负责人:Galit Alter
-
依托单位:
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp
-
批准号:7686615
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2009
-
负责人:Galit Alter
-
依托单位:
海外基金